JP2011510303A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011510303A5 JP2011510303A5 JP2010543281A JP2010543281A JP2011510303A5 JP 2011510303 A5 JP2011510303 A5 JP 2011510303A5 JP 2010543281 A JP2010543281 A JP 2010543281A JP 2010543281 A JP2010543281 A JP 2010543281A JP 2011510303 A5 JP2011510303 A5 JP 2011510303A5
- Authority
- JP
- Japan
- Prior art keywords
- biomolecule
- borate
- apatite chromatography
- ionic species
- chromatography support
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 65
- 229910052586 apatite Inorganic materials 0.000 claims description 29
- 238000004587 chromatography analysis Methods 0.000 claims description 29
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 claims description 29
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims description 28
- 241000894007 species Species 0.000 claims description 22
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 14
- 239000011575 calcium Substances 0.000 claims description 14
- 229910052791 calcium Inorganic materials 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 13
- 150000002500 ions Chemical class 0.000 claims description 11
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 10
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 10
- 238000010828 elution Methods 0.000 claims description 10
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 8
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 8
- 230000003139 buffering effect Effects 0.000 claims description 6
- 239000004471 Glycine Substances 0.000 claims description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 4
- 229910021538 borax Inorganic materials 0.000 claims description 4
- 235000010339 sodium tetraborate Nutrition 0.000 claims description 4
- WUUHFRRPHJEEKV-UHFFFAOYSA-N tripotassium borate Chemical compound [K+].[K+].[K+].[O-]B([O-])[O-] WUUHFRRPHJEEKV-UHFFFAOYSA-N 0.000 claims description 4
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 claims description 4
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical group C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- 239000004475 Arginine Substances 0.000 claims description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 claims description 2
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 claims description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 239000004202 carbamide Substances 0.000 claims description 2
- 229910052587 fluorapatite Inorganic materials 0.000 claims description 2
- 229940050410 gluconate Drugs 0.000 claims description 2
- 229940097042 glucuronate Drugs 0.000 claims description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims description 2
- 229940001447 lactate Drugs 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 229920000620 organic polymer Polymers 0.000 claims description 2
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical group [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 102000040430 polynucleotide Human genes 0.000 claims description 2
- 108091033319 polynucleotide Proteins 0.000 claims description 2
- 239000002157 polynucleotide Substances 0.000 claims description 2
- PHZLMBHDXVLRIX-UHFFFAOYSA-M potassium lactate Chemical compound [K+].CC(O)C([O-])=O PHZLMBHDXVLRIX-UHFFFAOYSA-M 0.000 claims description 2
- 239000001521 potassium lactate Substances 0.000 claims description 2
- 235000011085 potassium lactate Nutrition 0.000 claims description 2
- 229960001304 potassium lactate Drugs 0.000 claims description 2
- 238000000746 purification Methods 0.000 claims description 2
- 229940076788 pyruvate Drugs 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000001540 sodium lactate Substances 0.000 claims description 2
- 229940005581 sodium lactate Drugs 0.000 claims description 2
- 235000011088 sodium lactate Nutrition 0.000 claims description 2
- 229960005486 vaccine Drugs 0.000 claims description 2
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1151308P | 2008-01-18 | 2008-01-18 | |
| US61/011,513 | 2008-01-18 | ||
| US6266308P | 2008-01-28 | 2008-01-28 | |
| US61/062,663 | 2008-01-28 | ||
| US6985908P | 2008-03-19 | 2008-03-19 | |
| US61/069,859 | 2008-03-19 | ||
| US7084108P | 2008-03-27 | 2008-03-27 | |
| US61/070,841 | 2008-03-27 | ||
| US13578708P | 2008-07-24 | 2008-07-24 | |
| US61/135,787 | 2008-07-24 | ||
| US18946708P | 2008-08-20 | 2008-08-20 | |
| US61/189,467 | 2008-08-20 | ||
| PCT/US2009/031293 WO2009092010A1 (en) | 2008-01-18 | 2009-01-16 | Enhanced purification of phosphorylated and non-phosphorylated biomolecules by apatite chromatography |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011510303A JP2011510303A (ja) | 2011-03-31 |
| JP2011510303A5 true JP2011510303A5 (enExample) | 2012-03-01 |
| JP5624476B2 JP5624476B2 (ja) | 2014-11-12 |
Family
ID=40876787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010543281A Active JP5624476B2 (ja) | 2008-01-18 | 2009-01-16 | アパタイトクロマトグラフィーによるリン酸化生体分子および非リン酸化生体分子の向上した精製法 |
Country Status (4)
| Country | Link |
|---|---|
| US (5) | US20090186396A1 (enExample) |
| EP (4) | EP2287174B8 (enExample) |
| JP (1) | JP5624476B2 (enExample) |
| WO (2) | WO2009092014A1 (enExample) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2500413A1 (en) | 2006-09-13 | 2012-09-19 | Abbott Laboratories | Cell culture improvements |
| US8911964B2 (en) | 2006-09-13 | 2014-12-16 | Abbvie Inc. | Fed-batch method of making human anti-TNF-alpha antibody |
| EP2287174B8 (en) * | 2008-01-18 | 2016-12-07 | Bio-Rad Laboratories, Inc. | Enhanced purification of antibody fragments by apatite chromatography |
| US8834875B2 (en) | 2010-01-13 | 2014-09-16 | Oncomed Pharmaceuticals, Inc. | Notch1 binding agents and methods of use thereof |
| KR20110091678A (ko) * | 2008-10-20 | 2011-08-12 | 아보트 러보러터리즈 | 단백질 ａ 친화성 크로마토그래피를 이용한 항체의 분리 및 정제 |
| NZ592097A (en) | 2008-10-20 | 2013-01-25 | Abbott Lab | Viral inactivation during purification of il-12 and il-18 antibodies |
| EP2350130B1 (en) * | 2008-10-31 | 2018-10-03 | Wyeth LLC | Purification of acidic proteins using ceramic hydroxyapatite chromatography |
| US8907059B2 (en) * | 2008-11-14 | 2014-12-09 | Bio-Rad Laboratories, Inc. | Phosphopeptide enrichment of compositions by fractionation on ceramic hydroxyapatite |
| US20110229471A1 (en) | 2008-11-26 | 2011-09-22 | Cedars-Sinai Medical Center | Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease |
| JP2011097918A (ja) * | 2009-10-07 | 2011-05-19 | Hoya Corp | 精製方法およびワクチンの製造方法 |
| TWI535445B (zh) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Ｗｎｔ拮抗劑及治療和篩選方法 |
| EP2524215B1 (en) * | 2010-01-15 | 2018-12-26 | Bio-Rad Laboratories, Inc. | Surface neutralization of apatite |
| SG10201501342UA (en) | 2010-02-24 | 2015-04-29 | Immunogen Inc | Folate receptor 1 antibodies and immunoconjugates and uses thereof |
| SG10201501803YA (en) | 2010-03-12 | 2015-05-28 | Immunogen Inc | Cd37-binding molecules and immunoconjugates thereof |
| SG185601A1 (en) * | 2010-05-18 | 2012-12-28 | Abbvie Inc | Apparatus and process of purification of proteins |
| WO2012019024A2 (en) | 2010-08-04 | 2012-02-09 | Immunogen, Inc. | Her3-binding molecules and immunoconjugates thereof |
| US8895707B2 (en) | 2010-08-18 | 2014-11-25 | Bio-Rad Laboratories, Inc. | Elution of proteins from hydroxyapatite resins without resin deterioration |
| CA2812058C (en) * | 2010-09-20 | 2019-04-16 | Bio-Rad Laboratories, Inc. | Dissociation of product-complexed contaminants in chromatography |
| SG191186A1 (en) * | 2010-12-15 | 2013-07-31 | Baxter Int | Eluate collection using conductivity gradient |
| WO2012101671A1 (en) * | 2011-01-25 | 2012-08-02 | Jcr Pharmaceuticals Co., Ltd. | Method for production of human recombinant iduronate 2-sulfatase |
| WO2012106449A1 (en) | 2011-02-02 | 2012-08-09 | Bio-Rad Laboratories, Inc. | Apatite surface neutralization with alkali solutions |
| ES2865449T3 (es) | 2011-03-16 | 2021-10-15 | Hoffmann La Roche | Cromatografía de intercambio iónico con selectividad mejorada para la separación de monómeros, agregados y fragmentos polipeptídicos por modulación de la fase móvil |
| WO2012133269A1 (ja) * | 2011-03-29 | 2012-10-04 | 日本ケミカルリサーチ株式会社 | マンノース－６－リン酸の分析装置及び分析法 |
| US8911992B2 (en) * | 2011-04-28 | 2014-12-16 | Bio-Rad Laboratories, Inc. | DNA removal in target molecule purification |
| CN106167526A (zh) | 2011-07-15 | 2016-11-30 | 昂考梅德药品有限公司 | Rspo结合剂和其应用 |
| WO2013043608A1 (en) * | 2011-09-20 | 2013-03-28 | Bio-Rad Laboratories, Inc. | Removal of virucidal agents from biomolecule preparations |
| HRP20190044T1 (hr) | 2011-09-23 | 2019-02-22 | Oncomed Pharmaceuticals, Inc. | Agensi koji vežu vegf/dll4 i njihove uporabe |
| AU2012351751B2 (en) * | 2011-10-19 | 2017-09-07 | Novimmune S.A. | Methods of purifying antibodies |
| MX350957B (es) | 2011-11-23 | 2017-09-27 | Medimmune Llc | Moleculas de union especificas para her3 y usos de las mismas. |
| EP2855501B1 (en) | 2012-05-30 | 2018-04-25 | Bio-Rad Laboratories, Inc. | In situ restoration of apatite-based chromatography resins |
| WO2013184912A2 (en) | 2012-06-06 | 2013-12-12 | Oncomed Pharmaceuticals, Inc. | Binding agents that modulate the hippo pathway and uses thereof |
| US9200073B2 (en) | 2012-08-31 | 2015-12-01 | Immunogen, Inc. | Diagnostic assays and kits for detection of folate receptor 1 |
| US20140073766A1 (en) * | 2012-09-07 | 2014-03-13 | Avianax Llc | METHODS FOR PURIFYING IgY ANTIBODIES |
| AU2013334644B2 (en) * | 2012-10-24 | 2018-07-12 | Genzyme Corporation | Elution of biomolecules from multi-modal resins using mes and mops as mobile phase modifiers |
| US9327014B2 (en) | 2012-12-04 | 2016-05-03 | Oncomed Pharmaceuticals, Inc. | Immunotherapy with binding agents |
| EP3639841B1 (en) | 2013-03-27 | 2023-09-06 | Cedars-Sinai Medical Center | Treating fibrosis by inhibiting tl1a |
| CA2910770C (en) | 2013-07-12 | 2018-02-27 | Merck Patent Gmbh | Removal of fragments from a sample containing a target protein using activated carbon |
| EP3022295A4 (en) | 2013-07-19 | 2017-03-01 | Cedars-Sinai Medical Center | Signature of tl1a (tnfsf15) signaling pathway |
| CN118271429A (zh) | 2013-08-19 | 2024-07-02 | 豪夫迈·罗氏有限公司 | 用羟基磷灰石层析分离双特异性抗体和双特异性抗体生产副产物 |
| CA3222465A1 (en) | 2013-08-30 | 2015-03-05 | Immunogen, Inc. | Antibodies and assays for detection of folate receptor 1 |
| PT3055332T (pt) | 2013-10-08 | 2019-12-09 | Immunogen Inc | Regimes de dosagem de imunoconjugados anti-folr1 |
| MX2016007066A (es) | 2013-12-02 | 2016-09-08 | Oncomed Pharm Inc | Identificacion de marcadores biologicos predictivos asociados con inhibidores de la via de wnt. |
| CN118085103A (zh) | 2014-02-02 | 2024-05-28 | 麦迪穆有限责任公司 | 用于治疗疼痛的化合物和方法 |
| PT3128997T (pt) | 2014-04-08 | 2020-09-04 | Boston Pharmaceuticals Inc | Moléculas de ligação específicas para il-21 e suas utilizações |
| EP3129055B1 (en) | 2014-04-11 | 2020-07-01 | MedImmune, LLC | Bispecific her2 antibodies |
| JP2016003192A (ja) * | 2014-06-16 | 2016-01-12 | ＨＯＹＡ Ｔｅｃｈｎｏｓｕｒｇｉｃａｌ株式会社 | 緩衝液および精製方法 |
| CN105407917B (zh) * | 2014-06-23 | 2021-07-06 | 生物辐射实验室股份有限公司 | 磷灰石原位恢复 |
| EP3157689B1 (en) | 2014-06-23 | 2021-04-28 | Bio-Rad Laboratories, Inc. | Apatite pretreatment |
| TW201619200A (zh) | 2014-10-10 | 2016-06-01 | 麥迪紐有限責任公司 | 人類化抗－ｏｘ４０抗體及其用途 |
| US9938356B2 (en) | 2014-11-10 | 2018-04-10 | Medimmune Limited | Binding molecules specific for CD73 and uses thereof |
| HK1246304A1 (zh) | 2014-11-11 | 2018-09-07 | Medimmune Limited | 包含抗cd73抗体和a2a受体抑制剂的治疗组合及其用途 |
| JP6979877B2 (ja) | 2015-06-08 | 2021-12-15 | デビオファーム インターナショナル， エス． アー． | 抗ｃｄ３７イムノコンジュゲートおよび抗ｃｄ２０抗体の組み合わせ |
| BR112017027254A2 (pt) | 2015-06-29 | 2019-05-14 | Immunogen, Inc. | anticorpos anti-cd123 e conjugados e derivados dos mesmos |
| CN116440279A (zh) | 2015-09-17 | 2023-07-18 | 伊缪诺金公司 | 包含抗folr1免疫缀合物的治疗组合 |
| WO2017053705A1 (en) | 2015-09-23 | 2017-03-30 | Oncomed Pharmaceuticals, Inc. | Methods and compositions for treatment of cancer |
| HRP20241606T1 (hr) | 2015-10-21 | 2025-01-31 | Redcoat Solutions, Inc. | Uređaj za detekciju krevetnih stjenica |
| US10768172B2 (en) | 2015-10-21 | 2020-09-08 | Redcoat Solutions, Inc. | Anti-bed bug monoclonal antibodies and methods of making and uses thereof |
| HRP20200882T1 (hr) | 2015-11-10 | 2020-09-04 | Medimmune, Llc | Vezujuće molekule specifične za asct2 i njihova uporaba |
| ES2817751T3 (es) * | 2015-12-21 | 2021-04-08 | Pfizer | Purificación de conjugados de anticuerpo-fármaco mediante el uso de un gradiente de fosfato de sodio |
| KR102457751B1 (ko) | 2016-03-10 | 2022-10-21 | 악셀레론 파마 인코포레이티드 | 액티빈 타입 2 수용체 결합 단백질 및 이의 용도 |
| JP7082945B2 (ja) | 2016-03-17 | 2022-06-09 | シーダーズ―シナイ メディカル センター | Ｒｎａｓｅｔ２により炎症性腸疾患を診断する方法 |
| CA3018272A1 (en) | 2016-04-22 | 2017-10-26 | Acceleron Pharma Inc. | Alk7 binding proteins and uses thereof |
| ES2877548T3 (es) | 2016-06-02 | 2021-11-17 | Abbvie Inc | Agonista del receptor de glucocorticoides e inmunoconjugados del mismo |
| WO2018071345A1 (en) | 2016-10-11 | 2018-04-19 | Integrated Biotherapeutics, Inc. | Broadly neutralizing antibody targeting the ebolavirus glycoprotein internal fusion loop |
| SG11201903737PA (en) | 2016-10-26 | 2019-05-30 | Cedars Sinai Medical Center | Neutralizing anti-tl1a monoclonal antibodies |
| MX2019005772A (es) | 2016-11-23 | 2019-10-02 | Bioverativ Therapeutics Inc | Anticuerpos mono y biespecíficos que se unen al factor de coagulación ix y al factor de coagulación x. |
| US11964998B2 (en) | 2017-08-30 | 2024-04-23 | Fresenius Kabi Deutschland Gmbh | Method for purifying anti-IL-6 receptor antibodies |
| CA3072129A1 (en) * | 2017-08-30 | 2019-03-07 | Ares Trading S.A. | Method for purifying proteins |
| MA52366A (fr) | 2018-04-25 | 2021-03-03 | Prometheus Biosciences Inc | Anticorps anti-tl1a optimisés |
| JP6951051B2 (ja) * | 2018-05-24 | 2021-10-20 | ＨＯＹＡ Ｔｅｃｈｎｏｓｕｒｇｉｃａｌ株式会社 | 吸着剤の生産方法 |
| AU2019380595A1 (en) | 2018-11-15 | 2021-06-03 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with VEGF/DLL4 binding agent |
| US11447551B2 (en) | 2018-12-28 | 2022-09-20 | Sparx Bioscience Limited | Binding molecules specific for claudin 18.2, compositions and methods thereof, for the treatment of cancer and other diseases |
| WO2020247738A1 (en) * | 2019-06-07 | 2020-12-10 | Dyne Therapeutics, Inc. | Methods of preparing protein-oligonucleotide complexes |
| JP7504992B2 (ja) | 2019-10-24 | 2024-06-24 | プロメテウス バイオサイエンシーズ，インク． | Ｔｎｆ様リガンド１ａ（ｔｌ１ａ）に対するヒト化抗体およびその使用 |
| KR20230084199A (ko) | 2020-09-28 | 2023-06-12 | 메디뮨 리미티드 | 통증 치료를 위한 화합물 및 방법 |
| US11807685B2 (en) | 2021-08-05 | 2023-11-07 | The Uab Research Foundation | Anti-CD47 antibody and uses thereof |
| US20240425572A1 (en) | 2021-10-15 | 2024-12-26 | Regenxbio Inc. | Antibodies and methods of using thereof |
| CN116606370B (zh) * | 2023-07-21 | 2023-09-19 | 南京松天盛科生物科技有限公司 | 一种天然IgM纯化的方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5441635A (en) * | 1986-07-05 | 1995-08-15 | Asahi Kogaku Kogyo Kabushiki Kaisha | Packing material for liquid chromatography |
| US4798886A (en) * | 1986-03-24 | 1989-01-17 | Takeda Chemical Industries, Ltd. | Mutual separation of proteins |
| JP2507339B2 (ja) * | 1986-08-11 | 1996-06-12 | 三井東圧化学株式会社 | 粗ｔＰＡの精製方法 |
| US5108919A (en) * | 1988-06-24 | 1992-04-28 | Genentech, Inc. | Dna sequences encoding yeast ubiquitin hydrolase |
| JPH084490B2 (ja) * | 1988-07-30 | 1996-01-24 | 積水化学工業株式会社 | 生物学的試料の処理装置 |
| ATE238321T1 (de) * | 1996-02-06 | 2003-05-15 | Roche Diagnostics Gmbh | Verfahren zur herstellung von gereinigter nukleinsäure und deren verwendung |
| US5843731A (en) | 1996-09-05 | 1998-12-01 | Asahi Kogaku Kogyo Kabushiki Kaisha | Method for purifying plasmid DNA on calcium phosphate compound |
| JPH10127285A (ja) * | 1996-09-05 | 1998-05-19 | Asahi Optical Co Ltd | プラスミドｄｎａの単離方法 |
| JP4160652B2 (ja) * | 1998-05-22 | 2008-10-01 | キリンファーマ株式会社 | エンド−β−Ｎ−アセチルグルコサミニダーゼ遺伝子 |
| WO2003059935A2 (en) | 2001-12-21 | 2003-07-24 | Immunex Corporation | Methods for purifying protein |
| DE102004027816A1 (de) * | 2004-06-08 | 2006-01-05 | Bioceuticals Arzneimittel Ag | Verfahren zur Reinigung von Erythropoietin |
| US20080039425A1 (en) * | 2004-08-04 | 2008-02-14 | Allos Therapeutics, Inc. | Methods and Compositions to Reduce Tissue Irritation in Parenteral Formulations |
| DE102004044419B4 (de) * | 2004-09-14 | 2010-04-15 | Biotest Ag | Verfahren zur Aufreinigung eines von Willebrand Faktors mittels Hydroxylapatit-Durchlaufchromatographie |
| KR101482791B1 (ko) | 2005-03-11 | 2015-01-21 | 와이어쓰 엘엘씨 | 약한 분배성 크로마토그래피법 |
| US20060246544A1 (en) * | 2005-03-30 | 2006-11-02 | Neose Technologies,Inc. | Manufacturing process for the production of peptides grown in insect cell lines |
| US20100234577A1 (en) * | 2006-06-14 | 2010-09-16 | Smithkline Beecham Corporation | Methods for purifying antibodies using ceramic hydroxyapatite |
| US7691980B2 (en) | 2007-01-09 | 2010-04-06 | Bio-Rad Laboratories, Inc. | Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers |
| US7999085B2 (en) | 2007-01-09 | 2011-08-16 | Bio-Rad Laboratories, Inc. | Enhanced capacity and purification of protein by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers |
| EP2287174B8 (en) * | 2008-01-18 | 2016-12-07 | Bio-Rad Laboratories, Inc. | Enhanced purification of antibody fragments by apatite chromatography |
-
2009
- 2009-01-16 EP EP10178856.0A patent/EP2287174B8/en not_active Not-in-force
- 2009-01-16 US US12/355,686 patent/US20090186396A1/en not_active Abandoned
- 2009-01-16 EP EP20100178843 patent/EP2275431A3/en not_active Withdrawn
- 2009-01-16 EP EP09702238.8A patent/EP2238154B1/en not_active Not-in-force
- 2009-01-16 WO PCT/US2009/031298 patent/WO2009092014A1/en not_active Ceased
- 2009-01-16 WO PCT/US2009/031293 patent/WO2009092010A1/en not_active Ceased
- 2009-01-16 US US12/355,665 patent/US8093364B2/en not_active Expired - Fee Related
- 2009-01-16 EP EP09701572.1A patent/EP2242762B1/en not_active Not-in-force
- 2009-01-16 JP JP2010543281A patent/JP5624476B2/ja active Active
-
2011
- 2011-12-02 US US13/310,576 patent/US9127042B2/en active Active
-
2015
- 2015-08-05 US US14/819,334 patent/US9938317B2/en not_active Expired - Fee Related
-
2018
- 2018-03-02 US US15/910,702 patent/US10919930B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011510303A5 (enExample) | ||
| JP2013500711A5 (enExample) | ||
| JP5624476B2 (ja) | アパタイトクロマトグラフィーによるリン酸化生体分子および非リン酸化生体分子の向上した精製法 | |
| JP4250770B2 (ja) | カチオン交換クロマトグラフィーによるフォンビルブラント因子の精製 | |
| JP5772816B2 (ja) | アフィニティークロマトグラフィー用充填剤およびイムノグロブリンを単離する方法 | |
| JP2013517284A5 (enExample) | ||
| EA201500952A1 (ru) | Способы очистки рекомбинантного adamts13 и других белков и их композиции | |
| JP5773454B2 (ja) | アパタイトの表面中和方法 | |
| JP4250771B2 (ja) | カチオン交換クロマトグラフィーによる因子ＶＩＩＩ／ｖＷＦ複合体の精製方法 | |
| JP2007532477A5 (enExample) | ||
| JP2011525523A5 (enExample) | ||
| KR101908074B1 (ko) | 개선된 FVIII:C/FVIII:Ag의 비를 갖는 인자 VIII의 제조방법 | |
| RU2019109975A (ru) | Способы очистки антител | |
| JP2012510500A5 (enExample) | ||
| WO2014034457A1 (ja) | ミックスモード抗体アフィニティー分離マトリックスとそれを用いた精製方法および標的分子 | |
| RU2011125656A (ru) | Очистка полипептидов | |
| TW408129B (en) | Method for purifying human urinary thrombomodulin by using hydroxyapatite column | |
| JP2014518508A5 (enExample) | ||
| RU2012133474A (ru) | Очистка факторов свертывания крови | |
| JP2014094936A (ja) | 抗体の精製方法 | |
| JP2009039038A (ja) | 被分離物質の分離方法及び精製方法 | |
| JP3476242B2 (ja) | インフルエンザｈａ蛋白の精製方法 |